JP2015062348A - Method of removing endotoxin from cell - Google Patents
Method of removing endotoxin from cell Download PDFInfo
- Publication number
- JP2015062348A JP2015062348A JP2013196850A JP2013196850A JP2015062348A JP 2015062348 A JP2015062348 A JP 2015062348A JP 2013196850 A JP2013196850 A JP 2013196850A JP 2013196850 A JP2013196850 A JP 2013196850A JP 2015062348 A JP2015062348 A JP 2015062348A
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- cell culture
- culture
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 68
- 239000002158 endotoxin Substances 0.000 title claims abstract description 42
- 238000004113 cell culture Methods 0.000 claims abstract description 88
- 201000010099 disease Diseases 0.000 claims abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
- 239000006285 cell suspension Substances 0.000 claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 238000005406 washing Methods 0.000 claims description 40
- 230000002776 aggregation Effects 0.000 claims description 21
- 238000004220 aggregation Methods 0.000 claims description 21
- 239000003112 inhibitor Substances 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 108010088751 Albumins Proteins 0.000 claims description 8
- 102000009027 Albumins Human genes 0.000 claims description 8
- 239000003589 local anesthetic agent Substances 0.000 claims description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 5
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 5
- 229940050526 hydroxyethylstarch Drugs 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 abstract description 6
- 239000003130 blood coagulation factor inhibitor Substances 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 157
- 239000000243 solution Substances 0.000 description 41
- 210000001519 tissue Anatomy 0.000 description 19
- 239000000463 material Substances 0.000 description 18
- 238000007710 freezing Methods 0.000 description 16
- 230000008014 freezing Effects 0.000 description 16
- 239000000758 substrate Substances 0.000 description 16
- 239000002609 medium Substances 0.000 description 15
- 239000007788 liquid Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 13
- 238000010257 thawing Methods 0.000 description 12
- 239000002577 cryoprotective agent Substances 0.000 description 10
- 230000000735 allogeneic effect Effects 0.000 description 9
- 230000035899 viability Effects 0.000 description 9
- 238000005138 cryopreservation Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000001816 cooling Methods 0.000 description 6
- -1 polypropylene Polymers 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 150000003926 acrylamides Chemical class 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 230000017455 cell-cell adhesion Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000011013 endotoxin removal Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 229960005015 local anesthetics Drugs 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 210000004683 skeletal myoblast Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 208000028006 Corneal injury Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 241000239218 Limulus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 108010093965 Polymyxin B Proteins 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003855 balanced salt solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000000959 cryoprotective effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000024 polymyxin B Polymers 0.000 description 2
- 229960005266 polymyxin b Drugs 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960005196 titanium dioxide Drugs 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- XLPJNCYCZORXHG-UHFFFAOYSA-N 1-morpholin-4-ylprop-2-en-1-one Chemical compound C=CC(=O)N1CCOCC1 XLPJNCYCZORXHG-UHFFFAOYSA-N 0.000 description 1
- RESPXSHDJQUNTN-UHFFFAOYSA-N 1-piperidin-1-ylprop-2-en-1-one Chemical compound C=CC(=O)N1CCCCC1 RESPXSHDJQUNTN-UHFFFAOYSA-N 0.000 description 1
- WLPAQAXAZQUXBG-UHFFFAOYSA-N 1-pyrrolidin-1-ylprop-2-en-1-one Chemical compound C=CC(=O)N1CCCC1 WLPAQAXAZQUXBG-UHFFFAOYSA-N 0.000 description 1
- AKVUWTYSNLGBJY-UHFFFAOYSA-N 2-methyl-1-morpholin-4-ylprop-2-en-1-one Chemical compound CC(=C)C(=O)N1CCOCC1 AKVUWTYSNLGBJY-UHFFFAOYSA-N 0.000 description 1
- RASDUGQQSMMINZ-UHFFFAOYSA-N 2-methyl-1-piperidin-1-ylprop-2-en-1-one Chemical compound CC(=C)C(=O)N1CCCCC1 RASDUGQQSMMINZ-UHFFFAOYSA-N 0.000 description 1
- LVCMKNCJDCTPIB-UHFFFAOYSA-N 2-methyl-1-pyrrolidin-1-ylprop-2-en-1-one Chemical compound CC(=C)C(=O)N1CCCC1 LVCMKNCJDCTPIB-UHFFFAOYSA-N 0.000 description 1
- YQIGLEFUZMIVHU-UHFFFAOYSA-N 2-methyl-n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C(C)=C YQIGLEFUZMIVHU-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 206010011039 Corneal perforation Diseases 0.000 description 1
- 206010011044 Corneal scar Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- OXQKEKGBFMQTML-UHFFFAOYSA-N D-glycero-D-gluco-heptitol Natural products OCC(O)C(O)C(O)C(O)C(O)CO OXQKEKGBFMQTML-UHFFFAOYSA-N 0.000 description 1
- 208000018035 Dental disease Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 1
- 229920002302 Nylon 6,6 Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 1
- 101710133394 POU domain, class 3, transcription factor 2 Proteins 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- OXQKEKGBFMQTML-WAHCGKIUSA-N Perseitol Natural products OC[C@H](O)[C@H](O)C(O)[C@H](O)[C@H](O)CO OXQKEKGBFMQTML-WAHCGKIUSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 108010013296 Sericins Proteins 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical class C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000011000 absolute method Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- DMLAVOWQYNRWNQ-UHFFFAOYSA-N azobenzene Chemical group C1=CC=CC=C1N=NC1=CC=CC=C1 DMLAVOWQYNRWNQ-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000015322 bone marrow disease Diseases 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 208000015100 cartilage disease Diseases 0.000 description 1
- 108010015046 cell aggregation factors Proteins 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 231100000269 corneal opacity Toxicity 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 238000003851 corona treatment Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000012143 endoscopic resection Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 208000028299 esophageal disease Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 208000022949 middle ear disease Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- KAKALCZDCFZYRN-UHFFFAOYSA-N n-(2-ethoxyethyl)-2-methylprop-2-enamide Chemical compound CCOCCNC(=O)C(C)=C KAKALCZDCFZYRN-UHFFFAOYSA-N 0.000 description 1
- YLQHOUDDHYMERA-UHFFFAOYSA-N n-(2-ethoxyethyl)prop-2-enamide Chemical compound CCOCCNC(=O)C=C YLQHOUDDHYMERA-UHFFFAOYSA-N 0.000 description 1
- KPEKHIHQXHOSRM-UHFFFAOYSA-N n-(oxolan-2-ylmethyl)prop-2-enamide Chemical compound C=CC(=O)NCC1CCCO1 KPEKHIHQXHOSRM-UHFFFAOYSA-N 0.000 description 1
- FIBUWQFQYAAXHD-UHFFFAOYSA-N n-cyclopropyl-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NC1CC1 FIBUWQFQYAAXHD-UHFFFAOYSA-N 0.000 description 1
- LCXIFAOALNZGDO-UHFFFAOYSA-N n-cyclopropylprop-2-enamide Chemical compound C=CC(=O)NC1CC1 LCXIFAOALNZGDO-UHFFFAOYSA-N 0.000 description 1
- ZIWDVJPPVMGJGR-UHFFFAOYSA-N n-ethyl-2-methylprop-2-enamide Chemical compound CCNC(=O)C(C)=C ZIWDVJPPVMGJGR-UHFFFAOYSA-N 0.000 description 1
- SWPMNMYLORDLJE-UHFFFAOYSA-N n-ethylprop-2-enamide Chemical compound CCNC(=O)C=C SWPMNMYLORDLJE-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- OXQKEKGBFMQTML-BIVRFLNRSA-N perseitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OXQKEKGBFMQTML-BIVRFLNRSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- AAAQKTZKLRYKHR-UHFFFAOYSA-N triphenylmethane Chemical compound C1=CC=CC=C1C(C=1C=CC=CC=1)C1=CC=CC=C1 AAAQKTZKLRYKHR-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本発明は、細胞からエンドトキシンを除去する方法、該方法を用いた細胞培養物製造方法、該製造方法により製造された細胞培養物などに関する。 The present invention relates to a method for removing endotoxin from cells, a cell culture production method using the method, a cell culture produced by the production method, and the like.
エンドトキシンは、グラム陰性菌の細胞壁表面に存在するリポ多糖複合体であり、体内に入ると、極めて微量であっても発熱、血圧低下、白血球数減少、血液凝固異常、血管内皮細胞障害、毛細血管透過性亢進などの症状を引き起こし、ＤＩＣ（播種性血管内凝固症候群）、ＭＯＦ（多臓器不全）、エンドトキシンショックなどの致死率の高い疾患の原因ともなる。したがって、生体に対して使用する医薬品や医療器具などにおいては、こうした有害事象の発生を回避するため、エンドトキシンの厳重な管理が必要となる。しかしながら、エンドトキシンは環境中に広く存在しており、比較的容易に汚染が起こるため、エンドトキシンの除去または不活化のための手法が研究されている。エンドトキシンを除去する手法としては、例えば、限外ろ過膜や逆浸透膜などによるろ過、イオン交換クロマトグラフィー、蒸留、活性炭、ポリミキシンＢ、ヒスチジン、ヒスタミン、酸化チタン（特許文献１）、ケイ酸アルミニウム（特許文献２）などの種々の吸着剤による吸着などが、エンドトキシンを不活化する手法としては、例えば、熱、酸、アルカリによる処理などが、それぞれ知られている。しかしながら、いずれの方法も多くの問題点を含んでおり、現実的に応用可能な絶対的な方法は未だ見出されていない。 Endotoxin is a lipopolysaccharide complex that exists on the cell wall surface of Gram-negative bacteria. Once in the body, even in very small amounts, fever, blood pressure reduction, leukocyte count reduction, abnormal blood coagulation, vascular endothelial cell damage, capillaries It causes symptoms such as hyperpermeability, and causes mortality such as DIC (Disseminated Intravascular Coagulation Syndrome), MOF (Multiple Organ Failure), and endotoxin shock. Therefore, strict management of endotoxin is necessary in order to avoid the occurrence of such adverse events in pharmaceuticals and medical devices used for living bodies. However, since endotoxins are widely present in the environment and contamination occurs relatively easily, techniques for removing or inactivating endotoxins have been studied. Methods for removing endotoxin include, for example, filtration through ultrafiltration membranes and reverse osmosis membranes, ion exchange chromatography, distillation, activated carbon, polymyxin B, histidine, histamine, titanium oxide (Patent Document 1), aluminum silicate ( As methods for inactivating endotoxin by adsorption with various adsorbents such as Patent Document 2), for example, treatment with heat, acid, alkali, and the like are known. However, each method includes many problems, and an absolute method that can be practically applied has not yet been found.
一方、近年、損傷した組織等の修復のために、種々の細胞を移植する試みが行われている。例えば、狭心症、心筋梗塞などの虚血性心疾患により損傷した心筋組織の修復のために、胎児心筋細胞、骨格筋芽細胞、間葉系幹細胞、心臓幹細胞、ＥＳ細胞等の利用が試みられている（非特許文献１）。このような試みの一環として、スキャフォールドを利用して形成した細胞構造物や、細胞をシート状に形成したシート状細胞培養物が開発されてきた（特許文献３）。シート状細胞培養物の治療への応用については、火傷などによる皮膚損傷に対する培養表皮シートの利用、角膜損傷に対する角膜上皮シート状細胞培養物の利用、食道ガン内視鏡的切除に対する口腔粘膜シート状細胞培養物の利用などの検討が進められている。
このような細胞培養物を臨床応用する場合には、移植を受けるレシピエントに対する安全性を確保するうえで、エンドトキシンの管理が重要となる。しかしながら、上述のような従来のエンドトキシンの除去や不活化のための手法は、医療用化合物や医療器具などの非生物を対象としたものであり、生体である細胞に適用可能な手法は未だ知られていない。
On the other hand, in recent years, attempts have been made to transplant various cells in order to repair damaged tissues. For example, fetal cardiomyocytes, skeletal myoblasts, mesenchymal stem cells, cardiac stem cells, ES cells, etc. have been tried to repair myocardial tissue damaged by ischemic heart diseases such as angina pectoris and myocardial infarction. (Non-Patent Document 1). As part of such attempts, cell structures formed using scaffolds and sheet-shaped cell cultures in which cells are formed into sheets have been developed (Patent Document 3). For the application of sheet cell culture to the treatment, use of cultured epidermis sheet for skin damage caused by burns, use of corneal epithelial sheet cell culture for corneal injury, oral mucosa sheet for endoscopic resection of esophageal cancer Studies such as the use of cell cultures are ongoing.
When such a cell culture is applied clinically, management of endotoxin is important in ensuring the safety of the recipient undergoing transplantation. However, the conventional methods for removing and inactivating endotoxins as described above are intended for non-living organisms such as medical compounds and medical instruments, and methods applicable to living cells are still unknown. It is not done.
本発明の目的は、細胞に適用可能なエンドトキシン除去方法を提供することにある。 The objective of this invention is providing the endotoxin removal method applicable to a cell.
本発明者は、上記課題を解決するために鋭意研究を進める中、細胞懸濁液を、細胞凝集阻害剤を含む洗浄液で繰り返し２回以上洗浄することにより、細胞からエンドトキシンを効果的に除去できることを見出し、本発明を完成させた。 The present inventor is able to effectively remove endotoxin from cells by repeatedly washing a cell suspension twice or more with a washing solution containing a cell aggregation inhibitor while pursuing earnest research to solve the above problems. The present invention was completed.
すなわち、本発明は以下に関する。
[１]細胞懸濁液を、細胞凝集阻害剤を含む洗浄液で繰り返し２回以上洗浄するステップを含む、細胞からエンドトキシンを除去する方法。
[２]洗浄するステップにおいて、細胞懸濁液を、細胞凝集阻害剤を含む洗浄液で繰り返し３〜１０回洗浄する、[１]に記載の方法。
[３]洗浄するステップにおいて、細胞懸濁液を、細胞凝集阻害剤を含む洗浄液で繰り返し６回洗浄する、[２]に記載の方法。
[４]細胞凝集阻害剤が、アルブミン、トレハロース、ヒドロキシエチルデンプン、デキストラン、局所麻酔薬からなる群から選択される、[１]〜[３]のいずれかに記載の方法。
[５][１]〜[４]のいずれかに記載の方法を含む、医療用細胞培養物の製造方法。
[６][５]に記載の方法で製造された、医療用細胞培養物。
[７][６]に記載の医療用細胞培養物を含む、医薬組成物。
[８]対象において疾患を処置する方法であって、[６]に記載の細胞培養物または[７]に記載の医薬組成物の有効量をそれ必要とする対象に移植するステップを含む、前記方法。
That is, the present invention relates to the following.
[1] A method for removing endotoxin from cells, comprising a step of repeatedly washing a cell suspension with a washing solution containing a cell aggregation inhibitor two or more times.
[2] The method according to [1], wherein in the washing step, the cell suspension is repeatedly washed 3 to 10 times with a washing solution containing a cell aggregation inhibitor.
[3] The method according to [2], wherein in the washing step, the cell suspension is repeatedly washed 6 times with a washing solution containing a cell aggregation inhibitor.
[4] The method according to any one of [1] to [3], wherein the cell aggregation inhibitor is selected from the group consisting of albumin, trehalose, hydroxyethyl starch, dextran, and a local anesthetic.
[5] A method for producing a medical cell culture, comprising the method according to any one of [1] to [4].
[6] A medical cell culture produced by the method according to [5].
[7] A pharmaceutical composition comprising the medical cell culture according to [6].
[8] A method for treating a disease in a subject, comprising the step of transplanting an effective amount of the cell culture according to [6] or the pharmaceutical composition according to [7] to a subject in need thereof. Method.
本発明のエンドトキシン除去方法により、生体に有害な量のエンドトキシンを含まない、安全性の高い医療用細胞培養物を製造することができるため、エンドトキシンによるリスクを回避することが可能となり、医療用細胞培養物を用いた処置の普及拡大が期待できる。また、本発明のエンドトキシン除去方法は細胞への負担が少なく、細胞培養物の治療活性を維持することができる。 The endotoxin removal method of the present invention makes it possible to produce a highly safe medical cell culture that does not contain an amount of endotoxin harmful to the living body. The spread of treatment using culture can be expected. In addition, the endotoxin removal method of the present invention places little burden on the cells and can maintain the therapeutic activity of the cell culture.
本明細書において別様に定義されない限り、本明細書で用いる全ての技術用語および科学用語は、当業者が通常理解しているものと同じ意味を有する。本明細書中で参照する全ての特許、出願、公開された出願および他の出版物は、その全体を参照により本明細書に援用する。 Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. All patents, applications, published applications and other publications referenced herein are hereby incorporated by reference in their entirety.
本発明の一側面は、細胞懸濁液を、細胞凝集阻害剤を含む洗浄液で繰り返し２回以上洗浄するステップを含む、細胞からエンドトキシンを除去する方法（以下、「除去方法」と略す場合もある）に関する。
本発明の除去方法における細胞は特に限定されず、任意の種類のものを包含するが、医療目的で使用されるものが好ましい。医療目的としては、限定されずに例えば疾患の処置、移植医療、再生医療などが挙げられる。かかる目的で使用する細胞としては、限定されずに、例えば、血液疾患などの治療に用いる造血幹細胞、免疫療法などに用いるリンパ球、樹状細胞などの免疫細胞、シート状細胞培養物を形成し得る細胞、例えば、筋芽細胞（例えば、骨格筋芽細胞など）、間葉系幹細胞（例えば、骨髄、脂肪組織、末梢血、皮膚、毛根、筋組織、子宮内膜、胎盤、臍帯血由来のものなど）、心筋細胞、線維芽細胞、心臓幹細胞、胚性幹細胞、ｉＰＳ細胞、滑膜細胞、軟骨細胞、上皮細胞（例えば、口腔粘膜上皮細胞、網膜色素上皮細胞、鼻粘膜上皮細胞など）、内皮細胞（例えば、血管内皮細胞など）、肝細胞（例えば、肝実質細胞など）、膵細胞（例えば、膵島細胞など）、腎細胞、副腎細胞、歯根膜細胞、歯肉細胞、骨膜細胞、皮膚細胞等が挙げられる。
One aspect of the present invention is a method for removing endotoxin from cells (hereinafter sometimes abbreviated as “removal method”), which includes a step of repeatedly washing a cell suspension with a washing solution containing a cell aggregation inhibitor twice or more. )
The cells in the removal method of the present invention are not particularly limited, and include any type, but those used for medical purposes are preferred. Examples of medical purposes include, but are not limited to, disease treatment, transplantation medicine, and regenerative medicine. The cells used for this purpose are not limited, and form, for example, hematopoietic stem cells used for treatment of blood diseases, lymphocytes used for immunotherapy, etc., dendritic cells and other immune cells, and sheet-like cell cultures. Derived cells such as myoblasts (eg skeletal myoblasts), mesenchymal stem cells (eg bone marrow, adipose tissue, peripheral blood, skin, hair root, muscle tissue, endometrium, placenta, cord blood) ), Cardiomyocytes, fibroblasts, cardiac stem cells, embryonic stem cells, iPS cells, synovial cells, chondrocytes, epithelial cells (eg, oral mucosal epithelial cells, retinal pigment epithelial cells, nasal mucosal epithelial cells, etc.), Endothelial cells (eg, vascular endothelial cells), hepatocytes (eg, hepatocytes), pancreatic cells (eg, islet cells), kidney cells, adrenal cells, periodontal ligament cells, gingival cells, periosteum cells, skin cells Etc.
細胞懸濁液は、細胞が、液体媒体中に浮遊した状態の液体を指す。液体媒体としては、細胞の操作に通常使用する任意の媒体、限定されずに、例えば、生理食塩水、リンゲル液、ハンクス平衡塩液などの平衡塩液、ＰＢＳ（リン酸緩衝生理食塩水）、液体培地などを用いることができる。浮遊細胞であれば、培養中の細胞を含む液体培地をそのまま細胞懸濁液としてもよいが、培地を上記の液体媒体と置換して細胞懸濁液を調製することも可能である。付着細胞であれば、培養中の細胞を基材から剥離し、これを上記の液体媒体に懸濁して細胞懸濁液を調製することができる。 A cell suspension refers to a liquid in which cells are suspended in a liquid medium. The liquid medium is not limited to any medium that is usually used for cell manipulation. Examples thereof include balanced salt solutions such as physiological saline, Ringer's solution, Hank's balanced salt solution, PBS (phosphate buffered saline), and liquid. A culture medium etc. can be used. In the case of floating cells, a liquid medium containing cells in culture may be used as a cell suspension as it is, but it is also possible to prepare a cell suspension by replacing the medium with the liquid medium. If it is an adherent cell, the cell in culture can be peeled from the substrate and suspended in the liquid medium to prepare a cell suspension.
本発明の除去方法における細胞凝集阻害剤は、細胞を洗浄する際に細胞同士の凝集を阻害できる物質であれば特に限定されず、下記実施例で用いたアルブミンのほか、細胞凝集阻害作用が知られている既知の任意の化合物、例えば、トレハロース、ヒドロキシエチルデンプン、デキストラン（WO 2012/063870）、局所麻酔薬（特開2006-42693）などを含む。アルブミンとしては、血清アルブミン、特に同種の血清アルブミンを用いることが好ましいが、卵アルブミン、乳アルブミン、筋アルブミンなどを用いることもできる。ここで「同種」とは、細胞を投与する対象（レシピエント）と同一の種の生物に由来することを意味する。例えば、投与する対象がヒトである場合、ヒトアルブミンが同種のアルブミンに該当する。局所麻酔薬としては、限定されずに、例えば、リドカイン、メピバカイン、ジブカイン、ブピバカイン、プロピトカイン等のアミド型局所麻酔薬、コカイン、プロカイン、クロロカイン、テトラカイン等のエステル型局所麻酔薬などが挙げられる。 The cell aggregation inhibitor in the removal method of the present invention is not particularly limited as long as it is a substance that can inhibit aggregation between cells when washing cells. In addition to albumin used in the following examples, cell aggregation inhibitory activity is known. And any known compounds such as trehalose, hydroxyethyl starch, dextran (WO 2012/063870), local anesthetics (JP 2006-42693) and the like. As albumin, it is preferable to use serum albumin, particularly the same kind of serum albumin, but egg albumin, milk albumin, muscle albumin and the like can also be used. Here, “same species” means derived from the same species of organism as the subject (recipient) to which the cells are administered. For example, when the subject to be administered is a human, human albumin corresponds to the same kind of albumin. Examples of the local anesthetic include, but are not limited to, amide type local anesthetics such as lidocaine, mepivacaine, dibucaine, bupivacaine, propitocaine, and ester type local anesthetics such as cocaine, procaine, chlorocaine, and tetracaine.
細胞凝集阻害剤の濃度は、細胞を洗浄する際に細胞同士の凝集を阻害できるものであれば特に限定されないが、例えば、アルブミンであれば、好ましくは０．１〜５％（ｗ/ｖ）、より好ましくは０．２５〜２.５％（ｗ/ｖ）であり、トレハロースであれば、好ましくは４．５３〜３６２．４ｍｇ／ｍｌ、より好ましくは１５．１〜１８１．２ｍｇ／ｍｌであり、ヒドロキシエチルデンプンであれば、好ましくは１〜５００ｍｇ／ｍｌ、より好ましくは１０〜１００ｍｇ／ｍｌであり、デキストランであれば、好ましくは１〜５００ｍｇ／ｍｌ、より好ましくは１０〜２００ｍｇ／ｍｌ、より一層好ましくは３０〜１２５ｍｇ／ｍｌ、さらに好ましくは３０〜１００ｍｇ／ｍｌ、さらにより好ましくは６５〜１００ｍｇ／ｍｌであり、局所麻酔薬であれば、好ましくは０．１〜５重量％、より好ましくは０．５〜２.５重量％、最も好ましくは約１重量％である。 The concentration of the cell aggregation inhibitor is not particularly limited as long as it can inhibit aggregation between cells when washing the cells. For example, in the case of albumin, the concentration is preferably 0.1 to 5% (w / v). More preferably 0.25 to 2.5% (w / v), and trehalose is preferably 4.53 to 362.4 mg / ml, more preferably 15.1 to 181.2 mg / ml. If it is hydroxyethyl starch, it is preferably 1 to 500 mg / ml, more preferably 10 to 100 mg / ml, and if it is dextran, it is preferably 1 to 500 mg / ml, more preferably 10 to 200 mg / ml, Even more preferably 30 to 125 mg / ml, even more preferably 30 to 100 mg / ml, even more preferably 65 to 100 mg / ml. If, preferably 0.1 to 5% by weight, more preferably 0.5 to 2.5 wt%, and most preferably from about 1 wt%.
本発明の除去方法における洗浄液は、細胞凝集阻害剤が液体であれば、細胞凝集阻害剤のみから構成されてもよいし、細胞凝集阻害剤以外の成分、例えば希釈剤、緩衝剤、ｐＨ調整剤、浸透圧調整剤などを含んでいてもよい。細胞凝集阻害剤が固体の場合、洗浄液は、典型的には、上記成分のほか、細胞凝集阻害剤を溶解または懸濁する溶媒を含む。溶媒としては、限定されずに、例えば、生理食塩水、リンゲル液、ハンクス平衡塩液などの平衡塩液、ＰＢＳ（リン酸緩衝生理食塩水）、液体培地などが挙げられる。洗浄液は、細胞へのダメージを低減する観点から、体液の浸透圧と等しい等張液であることが好ましい。 If the cell aggregation inhibitor is a liquid, the cleaning liquid in the removal method of the present invention may be composed of only the cell aggregation inhibitor, or components other than the cell aggregation inhibitor, such as diluents, buffers, pH adjusters. Further, it may contain an osmotic pressure adjusting agent and the like. When the cell aggregation inhibitor is a solid, the washing solution typically contains a solvent for dissolving or suspending the cell aggregation inhibitor in addition to the above components. Examples of the solvent include, but are not limited to, physiological saline, Ringer's solution, balanced salt solution such as Hank's balanced salt solution, PBS (phosphate buffered saline), liquid medium, and the like. The washing solution is preferably an isotonic solution equal to the osmotic pressure of body fluid from the viewpoint of reducing damage to cells.
本発明の除去方法における洗浄は、培地の置換目的で行なわれている１〜２回程度のすすぎによる洗浄操作とは異なり、洗浄液に置換懸濁し、この細胞に混和撹拌操作を加えることにより洗浄を行うものをいう。この混和撹拌操作は、ピペッティングなどにより細胞に対して比較的強い力が加えられるものである。撹拌操作は、１回の洗浄あたり５回程度のピペッティングによる撹拌であることがエンドトキシンの効率的な除去と細胞の損傷防止の観点から望ましい。また洗浄回数は、洗浄液を交換して、２回以上行うことがエンドトキシンの除去に有効であるが、一方、１０回を超えて洗浄しても、洗浄効果は上がらず、むしろ細胞へのストレスが大きくなることが懸念されるため、２〜１０回とすることが好ましく、例えば、３〜９回、４〜８回または５〜７回とすることができる。中でも洗浄回数を６回とすることが特に好ましい。洗浄液の交換は、典型的には、洗浄液に懸濁させた細胞を遠心処理により沈殿させ、上清を廃棄し、沈殿した細胞を新たな洗浄液に懸濁することにより行うことができるが、同様の効果が得られる他の方法、例えば、細胞と洗浄液を濾過により分離する手法などを用いてもよい。 The washing in the removal method of the present invention is different from the washing operation by rinsing once or twice for the purpose of replacing the medium. Say what you do. In this mixing and stirring operation, a relatively strong force is applied to the cells by pipetting or the like. The stirring operation is preferably performed by pipetting about 5 times per washing from the viewpoint of efficient removal of endotoxin and prevention of cell damage. In addition, it is effective to remove endotoxin by exchanging the washing solution two or more times. On the other hand, washing more than 10 times does not increase the washing effect, but rather causes stress on the cells. Since it becomes a concern that it will become large, it is preferable to set it 2-10 times, for example, 3-9 times, 4-8 times, or 5-7 times. In particular, it is particularly preferable that the number of washings is six. Typically, the washing solution can be replaced by precipitating the cells suspended in the washing solution by centrifugation, discarding the supernatant, and suspending the precipitated cells in a new washing solution. For example, a method of separating the cells and the washing solution by filtration may be used.
本発明の除去方法において洗浄に用いる容器としては、細胞操作に通常用いるものを用いることができるが、エンドトキシンを吸着しやすい材質のものが、エンドトキシンのより効率的な除去の観点から好ましい。かかる材質としては、例えば、ポリプロピレン、ポリエチレン、ポリスチレンなどの疎水性物質が挙げられる。また、エンドトキシンを吸着することが知られている物質でコーティングされた容器を使用することもできる。エンドトキシンを吸着することが知られている物質としては、限定されずに、例えば、活性炭、ポリミキシンＢ、ヒスチジン、ヒスタミン、酸化チタン、ケイ酸アルミニウムなどが挙げられる。 As a container used for washing in the removal method of the present invention, a container usually used for cell manipulation can be used, but a material that easily adsorbs endotoxin is preferable from the viewpoint of more efficient removal of endotoxin. Examples of such materials include hydrophobic substances such as polypropylene, polyethylene, and polystyrene. Containers coated with substances known to adsorb endotoxins can also be used. Substances known to adsorb endotoxins include, but are not limited to, activated carbon, polymyxin B, histidine, histamine, titanium oxide, aluminum silicate, and the like.
本発明の別の側面は、本発明の除去方法を含む、医療用細胞培養物の製造方法（以下、「製造方法」と略す場合がある）、および、当該製造方法によって製造された医療用細胞培養物（以下、「細胞培養物」と略す場合がある）に関する。
本発明において「医療用」とは、医療用途、限定されずに例えば、疾患の処置、移植医療、再生医療などの用途に使用されることを意味する。したがって、本発明の「医療用細胞培養物」は、医療製品に求められる種々の基準、例えば、エンドトキシンに関する基準などを満たすものである。かかる基準としては、例えば、行政当局によって定められたものが挙げられる。例えば、現行の第十六改正日本薬局方において、エンドトキシンの規格値はＫ／Ｍとして設定され、ここでＫは発熱を誘起するといわれる体重１ｋｇ当たりのエンドトキシンの量（ＥＵ／ｋｇ）であり、投与経路による区分に基づき、脊髄腔内投与では０．２ＥＵ／ｋｇ、それ以外では５．０ＥＵ／ｋｇと設定されており、Ｍは体重１ｋｇ当たり１回に投与される最大量（頻回または持続的に投与される場合、Ｍは１時間以内に投与される最大総量）と設定されている。したがって、６０ｋｇの成人に最大で１回に細胞培養物１０ｍｌを静脈内注射する場合、上記規格値は３０ＥＵ／ｍｌとなる。ただし、これは単なる例示であり、当業者であれば、種々の状況に適合した基準値や規格値を適宜決定することができる。なお、医療は、ヒト医療および獣医療の両方を含む。
Another aspect of the present invention is a method for producing a medical cell culture (hereinafter sometimes abbreviated as “manufacturing method”) including the removal method of the present invention, and a medical cell produced by the production method. The present invention relates to a culture (hereinafter sometimes abbreviated as “cell culture”).
In the present invention, the term “medical use” means that it is used for medical purposes, for example, for treatment of diseases, transplantation medicine, regenerative medicine and the like. Therefore, the “medical cell culture” of the present invention satisfies various standards required for medical products, for example, standards for endotoxin. Examples of such standards include those set by administrative authorities. For example, in the current 16th revision Japanese Pharmacopoeia, the standard value of endotoxin is set as K / M, where K is the amount of endotoxin per kg body weight (EU / kg), which is said to induce fever, Based on the route of administration, it is set to 0.2 EU / kg for intrathecal administration, 5.0 EU / kg for other cases, and M is the maximum dose administered once per kg body weight (frequent or continuous) M is set to the maximum total dose administered within one hour). Therefore, when a 60 kg adult is intravenously injected with 10 ml of cell culture at a maximum, the above standard value is 30 EU / ml. However, this is merely an example, and those skilled in the art can appropriately determine a reference value and a standard value suitable for various situations. Medical care includes both human medical care and veterinary medical care.
本発明の好ましい態様において、細胞培養物は、３×１０７個の細胞を含む３ｍｌの細胞懸濁液において、１０ＥＵ／ｍｌ以上、好ましくは５ＥＵ／ｍｌ以上、より好ましくは１ＥＵ／ｍｌ以上、さらに好ましくは０．５ＥＵ／ｍｌ以上、より一層好ましくは０．２５ＥＵ／ｍｌ以上、特に好ましくは０．１３ＥＵ／ｍｌ以上のエンドトキシンを含まない。また、本発明の細胞培養物は、好ましくは、エンドトキシンを検出可能なレベルで含まない。エンドトキシンの検出は、既知の任意の方法、例えば、限定されずに、比濁法（例えばカイネティック−比濁法）、ゲル化法、比色法、合成基質法などのリムルス法などを用いることができる。 In a preferred embodiment of the present invention, the cell culture is 10 EU / ml or more, preferably 5 EU / ml or more, more preferably 1 EU / ml or more, in a 3 ml cell suspension containing 3 × 10 7 cells. Preferably it contains no more than 0.5 EU / ml, even more preferably 0.25 EU / ml or more, particularly preferably 0.13 EU / ml or more. Also, the cell culture of the present invention preferably does not contain endotoxin at a detectable level. Endotoxin detection may be performed by any known method, such as, but not limited to, a turbidimetric method (for example, kinetic-turbidimetric method), a gelation method, a colorimetric method, a Limulus method such as a synthetic substrate method, or the like. Can do.
本発明における細胞培養物は、細胞懸濁液や細胞構造体などの、医療用途に適した種々の形態をとることができる。細胞構造体は、シート状、柱状、塊状、栓状などの種々の形状であってよい。本発明においては、治療効果の高さなどの観点から、シート状の細胞構造体、すなわち、シート状細胞培養物が好ましい。「シート状細胞培養物」は、細胞が互いに連結してシート状になったものをいい、典型的には１の細胞層からなるものであるが、２以上の細胞層から構成されるものも含む。細胞同士は、直接（接着分子などの細胞要素を介するものを含む）および／または介在物質を介して、互いに連結していてもよい。介在物質としては、細胞同士を少なくとも物理的（機械的）に連結し得る物質であれば特に限定されないが、例えば、細胞外マトリックスなどが挙げられる。介在物質は、好ましくは細胞由来のもの、特に、細胞培養物を構成する細胞に由来するものである。細胞は少なくとも物理的（機械的）に連結されるが、さらに機能的、例えば、化学的、電気的に連結されてもよい。 The cell culture in the present invention can take various forms suitable for medical use, such as a cell suspension and a cell structure. The cell structure may have various shapes such as a sheet shape, a column shape, a block shape, and a plug shape. In the present invention, a sheet-like cell structure, that is, a sheet-like cell culture is preferable from the viewpoint of high therapeutic effect. “Sheet cell culture” refers to a sheet in which cells are connected to each other and is typically composed of one cell layer, but may also be composed of two or more cell layers. Including. The cells may be linked to each other directly (including those via cell elements such as adhesion molecules) and / or via intervening substances. The intervening substance is not particularly limited as long as it is a substance that can connect cells at least physically (mechanically), and examples thereof include an extracellular matrix. The intervening substance is preferably derived from cells, in particular, derived from the cells constituting the cell culture. The cells are at least physically (mechanically) connected, but may be further functionally, for example, chemically or electrically connected.
本発明の細胞培養物は、生体適合性や治療効果の高さなどの観点から、スキャフォールド（支持体）を含まないことが好ましい。スキャフォールドは、その表面上および／またはその内部に細胞を付着させ、細胞培養物の物理的一体性を維持するために当該技術分野において用いられることがあり、例えば、ポリビニリデンジフルオリド（ＰＶＤＦ）製の膜等が知られているが、本発明の好ましい細胞培養物は、かかるスキャフォールドがなくともその物理的一体性を維持することができるものである。また、本発明の細胞培養物は、好ましくは、細胞培養物を構成する細胞由来の物質のみからなり、それら以外の物質を含まない。 The cell culture of the present invention preferably does not contain a scaffold (support) from the viewpoints of biocompatibility and high therapeutic effect. Scaffolds may be used in the art to attach cells on and / or within its surface and maintain the physical integrity of the cell culture, eg, polyvinylidene difluoride (PVDF) Although preferred membranes of the present invention are known, the physical integrity thereof can be maintained without such a scaffold. In addition, the cell culture of the present invention preferably consists only of substances derived from the cells constituting the cell culture and does not contain any other substances.
本発明の細胞培養物に用いる細胞は、細胞培養物による治療が可能な任意の多細胞生物（例えば動物など）に由来し得る。かかる生物には、限定されずに、例えば、ヒト、非ヒト霊長類、イヌ、ネコ、ブタ、ウマ、ヤギ、ヒツジ、げっ歯目動物（例えば、マウス、ラット、ハムスター、モルモットなど）、ウサギなどの哺乳動物が含まれる。また、細胞培養物の形成に用いる細胞は１種類のみであってもよいが、２種類以上の細胞を用いることもできる。本発明の好ましい態様において、細胞培養物を形成する細胞が２種類以上ある場合、最も多い細胞の比率（純度）は、細胞培養物製造終了時において、６０％以上、好ましくは７０％以上、より好ましくは７５％以上である。 The cells used in the cell culture of the present invention can be derived from any multicellular organism that can be treated with the cell culture (such as animals). Examples of such organisms include, but are not limited to, humans, non-human primates, dogs, cats, pigs, horses, goats, sheep, rodents (eg, mice, rats, hamsters, guinea pigs, etc.), rabbits, and the like. Of mammals. Further, only one type of cell may be used for forming the cell culture, but two or more types of cells may be used. In a preferred embodiment of the present invention, when there are two or more types of cells forming a cell culture, the ratio (purity) of the most cells is 60% or more, preferably 70% or more at the end of cell culture production. Preferably it is 75% or more.
細胞は異種由来細胞であっても同種由来細胞であってもよい。ここで「異種由来細胞」は、細胞培養物が移植に用いられる場合、そのレシピエントとは異なる種の生物に由来する細胞を意味する。例えば、レシピエントがヒトである場合、サルやブタに由来する細胞などが異種由来細胞に該当する。また、「同種由来細胞」は、レシピエントと同一の種の生物に由来する細胞を意味する。例えば、レシピエントがヒトである場合、ヒト細胞が同種由来細胞に該当する。同種由来細胞は、自己由来細胞（自己細胞または自家細胞ともいう）、すなわち、レシピエントに由来する細胞と、同種非自己由来細胞（他家細胞ともいう）を含む。自己由来細胞は、移植しても拒絶反応が生じないため、本発明においては好ましい。しかしながら、異種由来細胞や同種非自己由来細胞を利用することも可能である。異種由来細胞や同種非自己由来細胞を利用する場合は、拒絶反応を抑制するため、免疫抑制処置が必要となることがある。なお、本明細書中で、自己由来細胞以外の細胞、すなわち、異種由来細胞と同種非自己由来細胞を非自己由来細胞と総称することもある。本発明の一態様において、細胞は自家細胞または他家細胞である。本発明の一態様において、細胞は自家細胞である。本発明の別の態様において、細胞は他家細胞である。 The cell may be a xenogeneic cell or a homologous cell. As used herein, “heterologous cell” means a cell derived from an organism of a species different from the recipient when the cell culture is used for transplantation. For example, when the recipient is a human, cells derived from monkeys or pigs correspond to xenogeneic cells. The “same species-derived cell” means a cell derived from an organism of the same species as the recipient. For example, when the recipient is a human, the human cell corresponds to the allogeneic cell. The allogeneic cells include autologous cells (also referred to as autologous cells or autologous cells), that is, cells derived from the recipient, and allogeneic non-autologous cells (also referred to as allogeneic cells). Autologous cells are preferred in the present invention because no rejection occurs even after transplantation. However, it is also possible to use heterologous cells or allogeneic non-autologous cells. When using heterologous cells or allogeneic non-autologous cells, immunosuppressive treatment may be required to suppress rejection. In the present specification, cells other than autologous cells, that is, heterologous cells and allogeneic nonautologous cells may be collectively referred to as nonautologous cells. In one embodiment of the invention, the cells are autologous cells or allogeneic cells. In one embodiment of the present invention, the cell is an autologous cell. In another embodiment of the invention, the cell is an allogeneic cell.
本発明の細胞培養物は、種々の疾患、特に組織の異常に関連する疾患の処置に有用である。したがって、一態様において、本発明の細胞培養物は、組織の異常に関連する疾患の処置に用いるためのものである。処置の対象となる組織としては、限定されずに、例えば、心筋、角膜、網膜、食道、皮膚、関節、軟骨、肝臓、膵臓、歯肉、腎臓、甲状腺、骨格筋、中耳、骨髄などが挙げられる。また、処置の対象となる疾患としては、限定されずに、例えば、心疾患（例えば、心筋傷害（心筋梗塞、心外傷）、心筋症など）、角膜疾患（例えば、角膜上皮幹細胞疲弊症、角膜損傷（熱・化学腐食）、角膜潰瘍、角膜混濁、角膜穿孔、角膜瘢痕、スティーブンス・ジョンソン症候群、眼類天疱瘡など）、網膜疾患（例えば、網膜色素変性症、加齢黄斑変性症など）、食道疾患（例えば、食道手術（食道ガン除去）後の食道の炎症・狭窄の予防など）、皮膚疾患（例えば、皮膚損傷（外傷、熱傷）など）、関節疾患（例えば、変形性関節炎など）、軟骨疾患（例えば、軟骨の損傷など）、肝疾患（例えば、慢性肝疾患など）、膵臓疾患（例えば、糖尿病など）、歯科疾患（例えば、歯周病など）、腎臓疾患（例えば、腎不全、腎性貧血、腎性骨異栄養症など）、甲状腺疾患（例えば、甲状腺機能低下症など）、筋疾患（例えば、筋損傷、筋炎など）、中耳疾患（例えば、中耳炎など）、骨髄疾患（例えば、白血病、再生不良性貧血、免疫不全疾患など）が挙げられる。 The cell culture of the present invention is useful for the treatment of various diseases, particularly diseases associated with tissue abnormalities. Accordingly, in one aspect, the cell culture of the present invention is for use in the treatment of diseases associated with tissue abnormalities. Examples of the tissue to be treated include, but are not limited to, myocardium, cornea, retina, esophagus, skin, joint, cartilage, liver, pancreas, gingiva, kidney, thyroid, skeletal muscle, middle ear, bone marrow, and the like. It is done. In addition, the disease to be treated is not limited, and for example, heart disease (eg, myocardial injury (myocardial infarction, cardiac injury), cardiomyopathy, etc.), corneal disease (eg, corneal epithelial stem cell exhaustion, cornea) Injury (heat / chemical corrosion), corneal ulcer, corneal opacity, corneal perforation, corneal scar, Stevens-Johnson syndrome, pemphigoid, etc., retinal diseases (eg retinitis pigmentosa, age-related macular degeneration) , Esophageal diseases (for example, prevention of esophageal inflammation / stenosis after esophageal surgery (esophageal cancer removal)), skin diseases (for example, skin damage (trauma, burn), etc.), joint diseases (for example, osteoarthritis, etc.) Cartilage disease (eg, cartilage damage), liver disease (eg, chronic liver disease), pancreatic disease (eg, diabetes), dental disease (eg, periodontal disease), kidney disease (eg, renal failure) Renal anemia, kidney Bone dystrophy), thyroid disease (eg, hypothyroidism), muscle disease (eg, muscle damage, myositis), middle ear disease (eg, otitis media), bone marrow disease (eg, leukemia, poor regeneration) Anemia, immunodeficiency diseases, etc.).
本発明の細胞培養物が上記疾患に有用であることは、例えば、特許文献３、非特許文献１、Arauchi et al., Tissue Eng Part A. 2009 Dec;15(12):3943-9、Ito et al., Tissue Eng. 2005 Mar-Apr;11(3-4):489-96、Yaji et al., Biomaterials. 2009 Feb;30(5):797-803、Yaguchi et al., Acta Otolaryngol. 2007 Oct;127(10):1038-44、Watanabe et al., Transplantation. 2011 Apr 15;91(7):700-6、Shimizu et al., Biomaterials. 2009 Oct;30(30):5943-9、Ebihara et al., Biomaterials. 2012 May;33(15):3846-51、Takagi et al., World J Gastroenterol. 2012 Oct 7;18(37):5145-50などに記載されている。 The usefulness of the cell culture of the present invention for the above-mentioned diseases is, for example, Patent Document 3, Non-Patent Document 1, Arauchi et al., Tissue Eng Part A. 2009 Dec; 15 (12): 3943-9, Ito et al., Tissue Eng. 2005 Mar-Apr; 11 (3-4): 489-96, Yaji et al., Biomaterials. 2009 Feb; 30 (5): 797-803, Yaguchi et al., Acta Otolaryngol. 2007 Oct; 127 (10): 1038-44, Watanabe et al., Transplantation. 2011 Apr 15; 91 (7): 700-6, Shimizu et al., Biomaterials. 2009 Oct; 30 (30): 5943-9 Ebihara et al., Biomaterials. 2012 May; 33 (15): 3846-51, Takagi et al., World J Gastroenterol. 2012 Oct 7; 18 (37): 5145-50, and the like.
本発明の細胞培養物は、処置の対象となる組織に適用し、これを修復、再生するために使用することもできるが、ホルモンなどの生理活性物質の給源として、処置の対象となる組織以外の部位（例えば、皮下組織など）に移植することもできる（例えば、Arauchi et al., Tissue Eng Part A. 2009 Dec;15(12):3943-9、Shimizu et al., Biomaterials. 2009 Oct;30(30):5943-9など）。また、本発明のシート状細胞培養物を注射可能な大きさに断片化し、これを処置が必要な部位に注射することもできる（Wang et al., Cardiovasc Res. 2008 Feb 1;77(3):515-24）。 Although the cell culture of the present invention can be applied to a tissue to be treated and used to repair and regenerate it, it can be used as a source of a physiologically active substance such as a hormone other than the tissue to be treated. (For example, Arauchi et al., Tissue Eng Part A. 2009 Dec; 15 (12): 3943-9, Shimizu et al., Biomaterials. 2009 Oct; 30 (30): 5943-9). It is also possible to fragment the sheet-like cell culture of the present invention into an injectable size and inject it into a site requiring treatment (Wang et al., Cardiovasc Res. 2008 Feb 1; 77 (3) : 515-24).
本発明の細胞培養物は、種々の追加成分、例えば、薬学的に許容し得る担体や、細胞培養物の生存性、生着性および／または機能などを高める成分、対象疾患の処置に有用な他の有効成分などをさらに含んでいてもよい。かかる追加成分としては、既知の任意のものを使用することができ、当業者はこれらの追加成分について精通している。また、本発明の細胞培養物は、細胞培養物の生存性、生着性および／または機能などを高める成分や、対象疾患の処置に有用な他の有効成分などと併用することができる。 The cell culture of the present invention is useful for treating various additional components such as a pharmaceutically acceptable carrier, a component that enhances the viability, engraftment and / or function of the cell culture, and the target disease. It may further contain other active ingredients. Any known additional components can be used, and those skilled in the art are familiar with these additional components. In addition, the cell culture of the present invention can be used in combination with components that enhance the viability, engraftment and / or function of the cell culture, and other active ingredients useful for treating the target disease.
本発明の細胞培養物は、本発明の除去方法でエンドトキシンが除去された細胞を用いて、既知の任意の方法により製造することができる。例えば、シート状細胞培養物の製造方法は、特許文献３、特開2010-081829、特開2010-226962、特開2010-226991、特開2011-110368、特開2011-115058、特開2011-172925などに記載されている。本発明の製造方法で用いる器具や、培地、試薬、添加物などの材料は、いずれもエンドトキシンを含まないことが好ましい。 The cell culture of the present invention can be produced by any known method using the cells from which endotoxin has been removed by the removal method of the present invention. For example, a method for producing a sheet-shaped cell culture is disclosed in Patent Document 3, JP 2010-081829, JP 2010-226962, JP 2010-226991, JP 2011-110368, JP 2011-115058, JP 2011-150 172925 and the like. It is preferable that any of the instruments used in the production method of the present invention and materials such as culture media, reagents and additives do not contain endotoxin.
本発明の製造方法の特に好ましい態様は、以下のステップを含む：
（１）細胞懸濁液を、細胞凝集阻害剤を含む洗浄液で繰り返し２回以上洗浄するステップ、
（２）ステップ（１）で得られた細胞を凍結するステップ、
（３）凍結した細胞を解凍するステップ、
（４）シート状細胞培養物を形成するステップ、
（５）形成されたシート状細胞培養物を回収するステップ。
（１）の洗浄するステップは、本発明の除去方法についてすでに上記したとおりである。
A particularly preferred embodiment of the production method of the present invention comprises the following steps:
(1) A step of repeatedly washing the cell suspension twice or more with a washing solution containing a cell aggregation inhibitor,
(2) freezing the cells obtained in step (1);
(3) thawing frozen cells;
(4) forming a sheet-like cell culture;
(5) A step of collecting the formed sheet-shaped cell culture.
The cleaning step (1) is as described above for the removal method of the present invention.
（２）の細胞を凍結するステップは、既知の任意の手法により行うことができる。かかる手法としては、限定されずに、例えば、容器内の細胞を、凍結手段、例えば、フリーザー、ディープフリーザー、低温の媒体（例えば、液体窒素等）に供することなどが挙げられる。凍結手段の温度は、容器内の細胞集団の一部、好ましくは全体を凍結させ得る温度であれば特に限定されないが、典型的には０℃以下、好ましくは−２０℃以下、より好ましくは−４０℃以下、さらに好ましくは−８０℃以下である。また、凍結操作における冷却速度は、凍結解凍後の細胞の生存率や機能を大きく損なうものでなければ特に限定されないが、典型的には４℃から冷却を始めて−８０℃に達するまで１〜５時間、好ましくは２〜４時間、特に約３時間かける程度の冷却速度である。具体的には、例えば、０．４６℃／分の速度で冷却することができる。かかる冷却速度は、所望の温度に設定した凍結手段に、細胞を含む容器を直接、または、凍結処理容器に収容して供することにより達成することができる。凍結処理容器は、容器内の温度の下降速度を所定の速度に制御する機能を有していてもよい。かかる凍結処理容器としては、既知の任意のもの、例えば、BICELL(R)（日本フリーザー）などを用いることができる。 The step of freezing the cells in (2) can be performed by any known technique. Such techniques include, but are not limited to, for example, subjecting the cells in the container to a freezing means such as a freezer, a deep freezer, or a low-temperature medium (for example, liquid nitrogen). The temperature of the freezing means is not particularly limited as long as it is a temperature at which a part of the cell population in the container, preferably the whole can be frozen, but is typically 0 ° C. or lower, preferably −20 ° C. or lower, more preferably − 40 ° C. or lower, more preferably −80 ° C. or lower. The cooling rate in the freezing operation is not particularly limited as long as it does not significantly impair the viability and function of the cells after freezing and thawing. Typically, the cooling rate is from 1 to 5 until cooling begins at 4 ° C and reaches -80 ° C. The cooling rate is on the order of time, preferably 2 to 4 hours, especially about 3 hours. Specifically, for example, cooling can be performed at a rate of 0.46 ° C./min. Such a cooling rate can be achieved by providing the container containing the cells directly or in a freezing treatment container in a freezing means set to a desired temperature. The freezing treatment container may have a function of controlling the temperature lowering speed in the container to a predetermined speed. As such a freezing container, any known container such as BICELL (R) (Japan Freezer) can be used.
凍結操作は、細胞を培養液や生理緩衝液などに浸漬させたまま行ってもよいが、細胞を凍結・解凍操作から保護するための凍結保護剤を培養液に加えたり、培養液を凍結保護剤を含む凍結保存液と置換するなどの処理を施したうえで行ってもよい。したがって、本発明の製造方法は、培養液に凍結保護剤を添加するステップ、または、培養液を凍結保存液に置換するステップをさらに含んでもよい。培養液を凍結保存液に置換する場合、凍結時に細胞が浸漬している液に有効濃度の凍結保護剤が含まれていれば、培養液を実質的に全て除去してから凍結保存液を添加しても、培養液を一部残したまま凍結保存液を添加してもよい。ここで、「有効濃度」とは、凍結保護剤が、毒性を示すことなく、凍結保護効果、例えば、凍結保護剤を用いない場合と比べた、凍結解凍後の細胞の生存率、活力、機能などの低下抑制効果を示す濃度を意味する。かかる濃度は当業者に知られているか、ルーチンの実験などにより適宜決定することができる。 The freezing operation may be performed while the cells are immersed in a culture solution or physiological buffer solution, but a cryoprotectant for protecting the cells from freezing and thawing operations is added to the culture solution, or the culture solution is cryoprotected. You may perform after performing the process of replacing with the cryopreservation liquid containing an agent. Therefore, the production method of the present invention may further include a step of adding a cryoprotectant to the culture solution or a step of replacing the culture solution with a cryopreservation solution. When replacing the culture solution with a cryopreservation solution, if the solution in which cells are immersed during freezing contains an effective concentration of cryoprotectant, remove the culture solution before adding the cryopreservation solution. Alternatively, the cryopreservation solution may be added while leaving a part of the culture solution. Here, the “effective concentration” means that the cryoprotectant exhibits a cryoprotective effect without exhibiting toxicity, for example, the viability, vitality, and function of the cell after freeze-thawing compared to the case where the cryoprotectant is not used. This means a concentration that exhibits a decrease-suppressing effect. Such a concentration is known to those skilled in the art or can be appropriately determined by routine experimentation.
凍結保護剤は、細胞に対して凍結保護作用を示すものであれば特に限定されずに、例えば、ジメチルスルホキシド（ＤＭＳＯ）、グリセロール、エチレングリコール、プロピレングリコール、セリシン、プロパンジオール、デキストラン、ポリビニルピロリドン、ポリビニルアルコール、ヒドロキシエチルデンプン、コンドロイチン硫酸、ポリエチレングリコール、ホルムアミド、アセトアミド、アドニトール、ペルセイトール、ラフィノース、ラクトース、トレハロース、スクロース、マンニトールなどを含む。凍結保護剤は、単独で用いても、２種または３種以上を組み合わせて用いてもよい。 The cryoprotectant is not particularly limited as long as it exhibits a cryoprotective action on cells, for example, dimethyl sulfoxide (DMSO), glycerol, ethylene glycol, propylene glycol, sericin, propanediol, dextran, polyvinylpyrrolidone, Polyvinyl alcohol, hydroxyethyl starch, chondroitin sulfate, polyethylene glycol, formamide, acetamide, adonitol, perseitol, raffinose, lactose, trehalose, sucrose, mannitol and the like. Cryoprotectants may be used alone or in combination of two or more.
培養液への凍結保護剤の添加濃度、または、凍結保存液中の凍結保護剤の濃度は、上記で定義した有効濃度であれば特に限定されず、典型的には、例えば、培養液または凍結保存液全体に対して２〜２０％（ｖ／ｖ）である。しかしながら、この濃度範囲からは外れるが、それぞれの凍結保護剤について知られているか、実験的に決定した代替的な使用濃度を採用することもでき、かかる濃度も本発明の範囲内である。 The concentration of the cryoprotectant added to the culture solution or the concentration of the cryoprotectant in the cryopreservation solution is not particularly limited as long as it is an effective concentration as defined above. It is 2 to 20% (v / v) with respect to the whole preservation solution. However, although outside this concentration range, alternative use concentrations known or experimentally determined for each cryoprotectant may be employed, and such concentrations are within the scope of the present invention.
（３）の凍結した細胞を解凍するステップは、既知の任意の細胞解凍手法により行うことができ、典型的には、例えば、凍結した細胞を、解凍手段、例えば、凍結温度より高い温度の固形、液状もしくはガス状の媒体（例えば、水）、ウォーターバス、インキュベーター、恒温器などに供したり、または、凍結した細胞を、凍結温度より高い温度の媒体（例えば、培養液）で浸漬することにより達成されるが、これに限定されない。解凍手段または浸漬媒体の温度は、細胞を所望の時間内に解凍できる温度であれば特に限定されないが、典型的には４〜５０℃、好ましくは３０℃〜４０℃、より好ましくは３６〜３８℃である。また、解凍時間は、解凍後の細胞の生存率や機能を大きく損なうものでなければ特に限定されないが、典型的には２分以内であり、特に２０秒以内とすることで生存率の低下を大幅に抑制することができる。解凍時間は、例えば、解凍手段または浸漬媒体の温度、凍結時の培養液または凍結保存液の容量もしくは組成などを変化させて調節することができる。 The step of thawing the frozen cells in (3) can be performed by any known cell thawing technique. Typically, for example, the frozen cells are solidified at a temperature higher than the freezing temperature by a thawing means. By using a liquid or gaseous medium (for example, water), a water bath, an incubator, a thermostat, etc., or by immersing a frozen cell in a medium (for example, a culture medium) at a temperature higher than the freezing temperature. Achieved but not limited to this. The temperature of the thawing means or the immersion medium is not particularly limited as long as the cells can be thawed within a desired time, but typically 4 to 50 ° C, preferably 30 to 40 ° C, more preferably 36 to 38. ° C. The thawing time is not particularly limited as long as it does not significantly impair the viability and function of the cells after thawing, but it is typically within 2 minutes, and in particular within 20 seconds can reduce the viability. It can be greatly suppressed. The thawing time can be adjusted, for example, by changing the temperature of the thawing means or the immersion medium, the volume or composition of the culture solution or cryopreservation solution at the time of freezing.
（４）のシート状細胞培養物を形成するステップは、既知の任意の手法により行うことができる。かかる手法としては、限定されずに、例えば、特許文献３、特開2010-081829、特開2010-226962、特開2010-226991、特開2011-110368、特開2011-115058、特開2011-172925などに記載されたものが挙げられる。シート状細胞培養物を形成するステップは、細胞を培養基材上に播種するステップ、および、播種した細胞をシート化するステップを含んでもよい。 The step of forming the sheet-shaped cell culture of (4) can be performed by any known technique. Such a method is not limited and is, for example, Patent Document 3, JP 2010-081829, JP 2010-226962, JP 2010-226991, JP 2011-110368, JP 2011-115058, JP 2011-150 172925 etc. are mentioned. Forming the sheet-shaped cell culture may include seeding the cells on a culture substrate and sheeting the seeded cells.
培養基材は、細胞がその上でシート状細胞培養物を形成し得るものであれば特に限定されず、例えば、種々の材質の容器、容器中の固形もしくは半固形の表面などを含む。容器は、培養液などの液体を透過させない構造・材料が好ましい。かかる材料としては、限定することなく、例えば、ポリエチレン、ポリプロピレン、テフロン（登録商標）、ポリエチレンテレフタレート、ポリメチルメタクリレート、ナイロン６，６、ポリビニルアルコール、セルロース、シリコン、ポリスチレン、ガラス、ポリアクリルアミド、ポリジメチルアクリルアミド、金属（例えば、鉄、ステンレス、アルミニウム、銅、真鍮）等が挙げられる。また、容器は、少なくとも１つの平坦な面を有することが好ましい。かかる容器の例としては、限定することなく、例えば、細胞培養皿、細胞培養ボトルなどが挙げられる。また、容器は、その内部に固形もしくは半固形の表面を有してもよい。固形の表面としては、上記のごとき種々の材料のプレートや容器などが、半固形の表面としては、ゲル、軟質のポリマーマトリックスなどが挙げられる。培養基材は、上記材料を用いて作製してもよいし、市販のものを利用してもよい。好ましい培養基材としては、限定することなく、例えば、シート状細胞培養物の形成に適した、接着性の表面を有する基材が挙げられる。具体的には、親水性の表面を有する基材、例えば、コロナ放電処理したポリスチレン、コラーゲンゲルや親水性ポリマーなどの親水性化合物を該表面にコーティングした基材、さらには、コラーゲン、フィブロネクチン、ラミニン、ビトロネクチン、プロテオグリカン、グリコサミノグリカンなどの細胞外マトリックスや、カドヘリンファミリー、セレクチンファミリー、インテグリンファミリーなどの細胞接着因子などを表面にコーティングした基材などが挙げられる。また、かかる基材は市販されている（例えば、Corning(R) TC-Treated Culture Dish、Corningなど）。 The culture substrate is not particularly limited as long as cells can form a sheet-like cell culture thereon, and includes, for example, containers of various materials, solid or semi-solid surfaces in containers, and the like. The container preferably has a structure / material that does not allow permeation of a liquid such as a culture solution. Examples of such materials include, but are not limited to, polyethylene, polypropylene, Teflon (registered trademark), polyethylene terephthalate, polymethyl methacrylate, nylon 6,6, polyvinyl alcohol, cellulose, silicon, polystyrene, glass, polyacrylamide, polydimethyl. Examples include acrylamide and metals (for example, iron, stainless steel, aluminum, copper, brass). The container preferably has at least one flat surface. Examples of such containers include, but are not limited to, cell culture dishes and cell culture bottles. Further, the container may have a solid or semi-solid surface therein. Examples of solid surfaces include plates and containers of various materials as described above, and examples of semi-solid surfaces include gels and soft polymer matrices. The culture substrate may be prepared using the above materials, or commercially available materials may be used. Preferable culture substrates include, but are not limited to, substrates having an adhesive surface suitable for the formation of sheet cell cultures. Specifically, a substrate having a hydrophilic surface, for example, a substrate coated with a hydrophilic compound such as polystyrene subjected to corona discharge treatment, collagen gel or hydrophilic polymer, and further, collagen, fibronectin, laminin , Substrates coated with an extracellular matrix such as vitronectin, proteoglycan and glycosaminoglycan, and cell adhesion factors such as cadherin family, selectin family and integrin family. Such base materials are commercially available (for example, Corning (R) TC-Treated Culture Dish, Corning, etc.).
培養基材は、刺激、例えば、温度や光に応答して物性が変化する材料で表面が被覆されていてもよい。かかる材料としては、限定されずに、例えば、（メタ）アクリルアミド化合物、Ｎ−アルキル置換（メタ）アクリルアミド誘導体（例えば、Ｎ−エチルアクリルアミド、Ｎ−ｎ−プロピルアクリルアミド、Ｎ−ｎ−プロピルメタクリルアミド、Ｎ−イソプロピルアクリルアミド、Ｎ−イソプロピルメタクリルアミド、Ｎ−シクロプロピルアクリルアミド、Ｎ−シクロプロピルメタクリルアミド、Ｎ−エトキシエチルアクリルアミド、Ｎ−エトキシエチルメタクリルアミド、Ｎ−テトラヒドロフルフリルアクリルアミド、Ｎ−テトラヒドロフルフリルメタクリルアミド等）、Ｎ，Ｎ−ジアルキル置換（メタ）アクリルアミド誘導体（例えば、Ｎ，Ｎ−ジメチル（メタ）アクリルアミド、Ｎ，Ｎ−エチルメチルアクリルアミド、Ｎ，Ｎ−ジエチルアクリルアミド等）、環状基を有する（メタ）アクリルアミド誘導体（例えば、１−（１−オキソ−２−プロペニル）−ピロリジン、１−（１−オキソ−２−プロペニル）−ピペリジン、４−（１−オキソ−２−プロペニル）−モルホリン、１−（１−オキソ−２−メチル−２−プロペニル）−ピロリジン、１−（１−オキソ−２−メチル−２−プロペニル）−ピペリジン、４−（１−オキソ−２−メチル−２−プロペニル）−モルホリン等）、またはビニルエーテル誘導体（例えば、メチルビニルエーテル）のホモポリマーまたはコポリマーからなる温度応答性材料、アゾベンゼン基を有する光吸収性高分子、トリフェニルメタンロイコハイドロオキシドのビニル誘導体とアクリルアミド系単量体との共重合体、および、スピロベンゾピランを含むＮ−イソプロピルアクリルアミドゲル等の光応答性材料などの公知のものを用いることができる（例えば、特開平2-211865、特開2003-33177参照）。これらの材料に所定の刺激を与えることによりその物性、例えば、親水性や疎水性を変化させ、同材料上に付着した細胞培養物の剥離を促進することができる。温度応答性材料で被覆された培養皿は市販されており（例えば、CellSeed Inc.のUpCell(R)）、これらを本発明の製造方法に使用することができる。 The surface of the culture substrate may be coated with a material whose physical properties change in response to stimulation, for example, temperature or light. Examples of such materials include, but are not limited to, (meth) acrylamide compounds, N-alkyl substituted (meth) acrylamide derivatives (for example, N-ethylacrylamide, Nn-propylacrylamide, Nn-propylmethacrylamide, N-isopropylacrylamide, N-isopropylmethacrylamide, N-cyclopropylacrylamide, N-cyclopropylmethacrylamide, N-ethoxyethylacrylamide, N-ethoxyethylmethacrylamide, N-tetrahydrofurfurylacrylamide, N-tetrahydrofurfurylmethacrylate Amides), N, N-dialkyl-substituted (meth) acrylamide derivatives (eg, N, N-dimethyl (meth) acrylamide, N, N-ethylmethylacrylamide, N, N-diethyl) Chloramide and the like), (meth) acrylamide derivatives having a cyclic group (for example, 1- (1-oxo-2-propenyl) -pyrrolidine, 1- (1-oxo-2-propenyl) -piperidine, 4- (1-oxo -2-propenyl) -morpholine, 1- (1-oxo-2-methyl-2-propenyl) -pyrrolidine, 1- (1-oxo-2-methyl-2-propenyl) -piperidine, 4- (1-oxo -2-methyl-2-propenyl) -morpholine), or a vinyl ether derivative (for example, methyl vinyl ether) homopolymer or copolymer, a temperature-responsive material, a light-absorbing polymer having an azobenzene group, triphenylmethane leucohydro Copolymer of vinyl derivative of oxide and acrylamide monomer, and spirobenzopyra It can be used to include N- and isopropyl acrylamide gels known, such as photoresponsive materials (e.g., JP-A-2-211865, see JP-2003-33177). By giving a predetermined stimulus to these materials, the physical properties, for example, hydrophilicity and hydrophobicity can be changed, and peeling of the cell culture adhered on the materials can be promoted. Culture dishes coated with a temperature-responsive materials are commercially available (e.g., UpCell of CellSeed Inc. (R)) can be used, these the production method of the present invention.
培養基材への細胞の播種は、既知の任意の手法および条件で行うことができる。培養基材への細胞の播種は、例えば、細胞を培養液に懸濁した細胞懸濁液を培養基材（培養容器）に注入することにより行ってもよい。細胞懸濁液の注入には、スポイトやピペットなど、細胞懸濁液の注入操作に適した器具を用いることができる。 Cell seeding on the culture substrate can be performed by any known technique and condition. The seeding of the cells on the culture substrate may be performed, for example, by injecting a cell suspension obtained by suspending the cells in the culture solution into the culture substrate (culture vessel). For the injection of the cell suspension, an apparatus suitable for the operation of injecting the cell suspension, such as a dropper or a pipette, can be used.
播種した細胞をシート化するステップも、既知の任意の手法および条件で行うことができる。かかる手法の非限定例は、例えば、特許文献３、特開2010-081829、特開2010-226962、特開2010-226991、特開2011-110368、特開2011-115058、特開2011-172925などに記載されている。細胞のシート化は、細胞同士が接着分子や、細胞外マトリックスなどの細胞間接着機構を介して互いに接着することにより達成されると考えられている。したがって、播種した細胞をシート化するステップは、例えば、細胞を、細胞間接着を形成する条件下で培養することにより達成することができる。かかる条件は、細胞間接着を形成することができればいかなるものであってもよいが、通常は一般的な細胞培養条件と同様の条件であれば細胞間接着を形成することができる。当業者であれば、播種する細胞の種類に応じて最適な条件を選択することができる。本明細書において、播種した細胞をシート化するための培養を、「シート化培養」と呼ぶ場合もある。 The step of forming the seeded cells into a sheet can also be performed by any known technique and condition. Non-limiting examples of such methods include, for example, Patent Document 3, JP 2010-081829, JP 2010-226962, JP 2010-226991, JP 2011-110368, JP 2011-115058, JP 2011-172925, and the like. It is described in. It is considered that the formation of a cell sheet is achieved when cells adhere to each other via an adhesion molecule or an intercellular adhesion mechanism such as an extracellular matrix. Therefore, the step of forming the seeded cells into a sheet can be achieved, for example, by culturing the cells under conditions that form cell-cell adhesion. Such conditions may be any as long as cell-cell adhesion can be formed, but cell-cell adhesion can usually be formed under the same conditions as general cell culture conditions. A person skilled in the art can select optimal conditions according to the type of cells to be seeded. In the present specification, the culture for forming the seeded cells into a sheet may be referred to as “sheet culture”.
培養に用いる細胞培養液（単に「培養液」もしくは「培地」と呼ぶ場合もある）は、細胞の生存を維持できるものであれば特に限定されないが、典型的には、アミノ酸、ビタミン類、電解質を主成分としたものが利用できる。本発明の一態様において、培養液は、細胞培養用の基礎培地をベースにしたものである。かかる基礎培地には、限定されずに、例えば、ＤＭＥＭ、ＭＥＭ、Ｆ１２、ＤＭＥ、ＲＰＭＩ１６４０、ＭＣＤＢ（ＭＣＤＢ１０２、１０４、１０７、１２０、１３１、１５３、１９９など）、Ｌ１５、ＳｋＢＭ、ＲＩＴＣ８０−７などが含まれる。これらの基礎培地の多くは市販されており、その組成も公知となっている。
基礎培地は、標準的な組成のまま（例えば、市販されたままの状態で）用いてもよいし、細胞種や細胞条件に応じてその組成を適宜変更してもよい。したがって、本発明に用いる基礎培地は、公知の組成のものに限定されず、１または２以上の成分が追加、除去、増量もしくは減量されたものを含む。
The cell culture medium used for the culture (sometimes simply referred to as “culture medium” or “medium”) is not particularly limited as long as it can maintain cell survival, but typically, amino acids, vitamins, electrolytes are used. Can be used. In one embodiment of the present invention, the culture solution is based on a basal medium for cell culture. Examples of such basal media include, but are not limited to, DMEM, MEM, F12, DME, RPMI 1640, MCDB (MCDB102, 104, 107, 120, 131, 153, 199, etc.), L15, SkBM, RITC80-7, and the like. included. Many of these basal media are commercially available, and their compositions are also known.
The basal medium may be used in a standard composition (for example, as it is commercially available), or the composition may be appropriately changed depending on the cell type and cell conditions. Therefore, the basal medium used in the present invention is not limited to those having a known composition, and includes one in which one or more components are added, removed, increased or decreased.
細胞の培養は、当該技術分野で通常なされている条件で行うことができる。例えば、典型的な培養条件としては、３７℃、５％ＣＯ２での培養が挙げられる。培養は任意の大きさおよび形状の容器で行うことができる。細胞培養物の大きさや形状は、培養容器の細胞付着面の大きさ・形状を調整すること、または、培養容器の細胞付着面に、所望の大きさ・形状の型枠を設置し、その内部で細胞を培養することなどにより任意に調節することができる。 Cell culture can be performed under conditions usually used in the art. For example, typical culture conditions include culture at 37 ° C. and 5% CO 2 . Culturing can be performed in containers of any size and shape. The size and shape of the cell culture can be adjusted by adjusting the size and shape of the cell adhesion surface of the culture vessel, or by installing a mold of the desired size and shape on the cell adhesion surface of the culture vessel. It can be arbitrarily adjusted by culturing the cells with, for example.
（５）におけるシート状細胞培養物の回収は、シート状細胞培養物が少なくとも部分的に、シート構造を保ったまま、足場となっている培養基材から遊離（剥離）できれば特に限定されず、例えば、タンパク質分解酵素（例えばトリプシンなど）による酵素処理および／またはピペッティングなどの機械的処理によって行うことができる。また、細胞を、刺激、例えば、温度や光に応答して物性が変化する材料で表面を被覆した培養基材上で培養して細胞培養物を形成した場合には、所定の刺激を加えることで、非酵素的に遊離することもできる。 The recovery of the sheet-shaped cell culture in (5) is not particularly limited as long as the sheet-shaped cell culture can be released (peeled) from the culture substrate serving as a scaffold while at least partially maintaining the sheet structure, For example, it can be performed by enzymatic treatment with a proteolytic enzyme (for example, trypsin) and / or mechanical treatment such as pipetting. In addition, when cells are cultured on a culture substrate whose surface is coated with a material that changes its physical properties in response to stimulation, for example, temperature or light, a predetermined stimulation is applied. It can also be released non-enzymatically.
本発明の別の側面は、本発明の細胞培養物を含む、医薬組成物に関する。
本発明の医薬組成物は、本発明の細胞培養物に加えて、種々の追加成分、例えば、薬学的に許容し得る担体や、細胞培養物の生存性、生着性および／または機能などを高める成分、対象疾患の処置に有用な他の有効成分などを含んでいてもよい。かかる追加成分としては、既知の任意のものを使用することができ、当業者はこれらの追加成分について精通している。また、本発明の医薬組成物は、細胞培養物の生存性、生着性および／または機能などを高める成分や、対象疾患の処置に有用な他の有効成分などと併用することができる。一態様において、本発明の医薬組成物は、組織の異常に関連する疾患の処置に用いるためのものである。処置の対象となる組織や疾患は、本発明の細胞培養物について上記したとおりである。
Another aspect of the present invention relates to a pharmaceutical composition comprising the cell culture of the present invention.
In addition to the cell culture of the present invention, the pharmaceutical composition of the present invention has various additional components such as a pharmaceutically acceptable carrier and the viability, engraftment and / or function of the cell culture. Ingredients that increase, other active ingredients useful in the treatment of the target disease, and the like may be included. Any known additional components can be used, and those skilled in the art are familiar with these additional components. In addition, the pharmaceutical composition of the present invention can be used in combination with components that enhance the viability, engraftment and / or function of cell cultures, and other active ingredients useful for treatment of target diseases. In one aspect, the pharmaceutical composition of the present invention is for use in the treatment of diseases associated with tissue abnormalities. The tissues and diseases to be treated are as described above for the cell culture of the present invention.
本発明の別の側面は、対象において疾患を処置する方法であって、本発明の細胞培養物または医薬組成物の有効量をそれ必要とする対象に投与するステップを含む方法に関する。本発明の処置方法の対象となる組織や疾患は、本発明の細胞培養物について上記したとおりである。また、本発明の処置方法においては、細胞培養物の生存性、生着性および／または機能などを高める成分や、対象疾患の処置に有用な他の有効成分などを、本発明の細胞培養物または医薬組成物と併用することができる。 Another aspect of the invention relates to a method of treating a disease in a subject, comprising the step of administering to a subject in need thereof an effective amount of a cell culture or pharmaceutical composition of the invention. The tissues and diseases to be treated by the treatment method of the present invention are as described above for the cell culture of the present invention. Further, in the treatment method of the present invention, components that enhance the viability, engraftment and / or function of the cell culture, and other active ingredients useful for the treatment of the target disease are used. Or it can use together with a pharmaceutical composition.
本発明の処置方法は、本発明の製造方法に従って、細胞培養物を製造するステップをさらに含んでもよい。本発明の処置方法は、細胞培養物を製造するステップの前に、対象から細胞培養物を製造するための細胞または細胞の給源となる組織を採取するステップをさらに含んでもよい。一態様において、細胞または細胞の給源となる組織を採取する対象は、細胞培養物の投与を処置を受ける対象と同一の個体である。別の態様において、細胞または細胞の給源となる組織を採取する対象は、細胞培養物の投与を処置を受ける対象とは同種の別個体である。別の態様において、細胞または細胞の給源となる組織を採取する対象は、細胞培養物の投与を処置を受ける対象とは異種の個体である。 The treatment method of the present invention may further include a step of producing a cell culture according to the production method of the present invention. The treatment method of the present invention may further include a step of collecting cells or a tissue serving as a source of cells for producing a cell culture from a subject before the step of producing the cell culture. In one embodiment, the subject from whom the cell or tissue from which the cell is derived is collected is the same individual as the subject receiving treatment of the cell culture. In another embodiment, the subject from whom the cell or tissue from which the cell is derived is collected is a separate species of the same type as the subject receiving treatment of the cell culture. In another embodiment, the subject from whom the cells or tissue from which the cells are derived is collected is an individual that is heterogeneous from the subject receiving treatment of the cell culture.
本発明において、用語「対象」は、任意の生物個体、好ましくは動物、さらに好ましくは哺乳動物、さらに好ましくはヒトの個体を意味する。本発明において、対象は健常であっても、何らかの疾患に罹患していてもよいものとするが、疾患の処置が企図される場合には、典型的には当該疾患に罹患しているか、罹患するリスクを有する対象を意味する。 In the context of the present invention, the term “subject” means any living individual, preferably an animal, more preferably a mammal, more preferably a human individual. In the present invention, the subject may be healthy or afflicted with some disease, but when treatment of the disease is intended, the subject is typically afflicted with or affected by the disease. Means a subject at risk.
また、用語「処置」は、疾患の治癒、一時的寛解または予防などを目的とする医学的に許容される全ての種類の予防的および／または治療的介入を包含するものとする。例えば、「処置」の用語は、疾患の進行の遅延または停止、病変の退縮または消失、当該疾患発症の予防または再発の防止などを含む、種々の目的の医学的に許容される介入を包含する。 The term “treatment” is also intended to encompass all types of medically acceptable prophylactic and / or therapeutic interventions intended to cure, temporarily ameliorate or prevent disease. For example, the term “treatment” encompasses medically acceptable interventions for various purposes, including delaying or stopping the progression of the disease, regression or disappearance of the lesion, prevention of the onset of the disease or prevention of recurrence, etc. .
本発明において、有効量とは、例えば、疾患の発症や再発を抑制し、症状を軽減し、または進行を遅延もしくは停止し得る量（例えば、細胞培養物に含まれる細胞数、細胞培養物のサイズ、重量など）であり、好ましくは、当該疾患の発症および再発を予防し、または当該疾患を治癒する量である。また、投与による利益を超える悪影響が生じない量が好ましい。かかる量は、例えば、マウス、ラット、イヌまたはブタなどの実験動物や疾患モデル動物における試験などにより適宜決定することができ、このような試験法は当業者によく知られている。また、処置の対象となる組織病変の大きさは、有効量決定のための重要な指標となり得る。 In the present invention, the effective amount means, for example, an amount that can suppress the onset or recurrence of a disease, reduce symptoms, or delay or stop progression (for example, the number of cells contained in a cell culture, Size, weight, etc.), preferably an amount that prevents the onset and recurrence of the disease or cures the disease. In addition, an amount that does not cause adverse effects exceeding the benefits of administration is preferred. Such an amount can be appropriately determined by, for example, testing in laboratory animals such as mice, rats, dogs or pigs, and disease model animals, and such test methods are well known to those skilled in the art. In addition, the size of the tissue lesion to be treated can be an important index for determining the effective amount.
本発明の細胞培養物および医薬組成物は、静脈内、筋肉内、皮下、局所、動脈内、門脈内、心室内、腹腔内等の種々の経路から投与することができる。シート状細胞培養物の場合は、投与方法として、典型的には組織への直接的な適用が挙げられるが、シート状細胞培養物の断片を用いる場合には、注射による投与が可能な種々の経路、例えば、静脈内、筋肉内、皮下、局所、動脈内、門脈内、心室内、腹腔内等の経路から投与してもよい。
投与頻度は、典型的には１回の処置につき１回であるが、所望の効果が得られない場合には、複数回投与することも可能である。
The cell culture and pharmaceutical composition of the present invention can be administered from various routes such as intravenous, intramuscular, subcutaneous, topical, intraarterial, intraportal, intraventricular, intraperitoneal and the like. In the case of a sheet-like cell culture, the administration method typically includes direct application to a tissue. However, when a fragment of a sheet-like cell culture is used, there are various methods that can be administered by injection. Administration may be via a route such as intravenous, intramuscular, subcutaneous, topical, intraarterial, intraportal, intraventricular, intraperitoneal, and the like.
The frequency of administration is typically once per treatment, but multiple administrations are possible if the desired effect is not obtained.
以下に、本発明を実施例を参照してより詳細に説明するが、これは本発明の特定の具体例を示すものであり、本発明はこれに限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to examples. However, this is a specific example of the present invention, and the present invention is not limited thereto.
実施例１ 細胞からのエンドトキシンの除去
２．５ｇのヒトアルブミン（一般社団法人日本血液製剤機構製）を５００ｍＬのハンクス平衡塩液に加え、ヒトアルブミンを０．５ｗ/ｖ％の濃度で含む洗浄液を調製した。３×１０７個のヒト骨格筋芽細胞を３０ｍＬの洗浄液に懸濁した細胞懸濁液を５０ｍＬコニカルチューブに入れ、そこにエンドトキシン（E. coli UKT-B株由来、和光純薬工業（株）製）を添加した。細胞懸濁液を１００μＬ採取し、その後エンドトキシン量の測定に供した。細胞懸濁液を２４０×ｇで７分間遠心して上清を廃棄した。チューブに洗浄液を２８．５ｍＬ加え、ピペッティングにより細胞を十分に撹拌した後、２４０×ｇで７分間遠心して上清を廃棄した。この操作を６回繰り返した。６回目の洗浄操作で、上清を廃棄した後に残った細胞を３ｍＬの洗浄液に懸濁し、エンドトキシン量の測定に供した。また、未使用の洗浄液もエンドトキシン量の測定に供した。なお、洗浄液には、一般的な作業条件下で混入する可能性のあるエンドトキシンの影響を評価するために、予め一定量のエンドトキシンを添加しておいた。各検体のエンドトキシン量は、トキシノメーターＥＴ−６０００およびリムルスＥＳ−ＩＩシングルテストワコー（いずれも和光純薬工業（株）製）を用いて比濁時間法（カイネティック−比濁法）にて測定した。結果を下表に示す。
Example 1 Removal of Endotoxin from Cells 2.5 g of human albumin (manufactured by Japan Blood Products Organization) was added to 500 mL of Hanks balanced salt solution, and a washing solution containing human albumin at a concentration of 0.5 w / v% was prepared. Prepared. A cell suspension obtained by suspending 3 × 10 7 human skeletal myoblasts in 30 mL of washing solution is placed in a 50 mL conical tube, and endotoxin (derived from E. coli UKT-B strain, Wako Pure Chemical Industries, Ltd.) Made) was added. 100 μL of the cell suspension was collected and then used for measurement of endotoxin level. The cell suspension was centrifuged at 240 × g for 7 minutes and the supernatant was discarded. After 28.5 mL of the washing solution was added to the tube and the cells were sufficiently stirred by pipetting, the supernatant was discarded by centrifugation at 240 × g for 7 minutes. This operation was repeated 6 times. In the sixth washing operation, the remaining cells after discarding the supernatant were suspended in 3 mL of washing solution and subjected to measurement of endotoxin level. In addition, an unused cleaning solution was also used for measuring the endotoxin amount. In addition, in order to evaluate the influence of endotoxin that may be mixed under general working conditions, a certain amount of endotoxin was added to the cleaning solution in advance. The amount of endotoxin in each specimen was determined by a turbidimetric time method (kinetic-turbidimetric method) using a Toxinometer ET-6000 and Limulus ES-II Single Test Wako (both manufactured by Wako Pure Chemical Industries, Ltd.). It was measured. The results are shown in the table below.
クリアランス（％）は、「（添加エンドトキシン量−洗浄後のエンドトキシン量）÷添加エンドトキシン量×１００」で計算した。
上記結果が示すとおり、本発明の除去方法により、細胞培養物に添加したエンドトキシンを、検出限界未満となるまで、実に９９．９５％超も除去することができた。
The clearance (%) was calculated by “(the amount of added endotoxin−the amount of endotoxin after washing) ÷ the amount of added endotoxin × 100”.
As the above results show, the removal method of the present invention was able to remove over 99.95% of the endotoxin added to the cell culture until it was below the detection limit.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013196850A JP6674727B2 (en) | 2013-09-24 | 2013-09-24 | How to remove endotoxin from cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013196850A JP6674727B2 (en) | 2013-09-24 | 2013-09-24 | How to remove endotoxin from cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015062348A true JP2015062348A (en) | 2015-04-09 |
| JP6674727B2 JP6674727B2 (en) | 2020-04-01 |
Family
ID=52830873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013196850A Active JP6674727B2 (en) | 2013-09-24 | 2013-09-24 | How to remove endotoxin from cells |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6674727B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111606978A (en) * | 2020-06-09 | 2020-09-01 | 河南省农业科学院 | Method for removing endotoxin in escherichia coli recombinant expression porcine parvovirus VP2 protein |
| CN113092767A (en) * | 2021-04-02 | 2021-07-09 | 丹娜(天津)生物科技股份有限公司 | Limulus reagent freeze-dried microsphere and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05255405A (en) * | 1991-12-24 | 1993-10-05 | Wako Pure Chem Ind Ltd | Method for extracting endotoxin |
| JP2007064895A (en) * | 2005-09-01 | 2007-03-15 | Wako Pure Chem Ind Ltd | Pretreatment method for endotoxin measurement of bio-applicable material and method for measuring endotoxin |
| JP2008136420A (en) * | 2006-12-01 | 2008-06-19 | Terumo Corp | Method for preparing medical cultured cell |
-
2013
- 2013-09-24 JP JP2013196850A patent/JP6674727B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05255405A (en) * | 1991-12-24 | 1993-10-05 | Wako Pure Chem Ind Ltd | Method for extracting endotoxin |
| JP2007064895A (en) * | 2005-09-01 | 2007-03-15 | Wako Pure Chem Ind Ltd | Pretreatment method for endotoxin measurement of bio-applicable material and method for measuring endotoxin |
| JP2008136420A (en) * | 2006-12-01 | 2008-06-19 | Terumo Corp | Method for preparing medical cultured cell |
Non-Patent Citations (2)
| Title |
|---|
| "３．５筋芽細胞シートによる重症心不全治療", 再生医療叢書３ 循環器, vol. 初版第１刷, JPN6017002963, 20 March 2013 (2013-03-20), pages p. 48-49 * |
| "エンドトキシンと医薬品の品質管理", 国立衛研報, vol. 第１２６号, JPN6017035194, 2008, pages p. 19-33 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111606978A (en) * | 2020-06-09 | 2020-09-01 | 河南省农业科学院 | Method for removing endotoxin in escherichia coli recombinant expression porcine parvovirus VP2 protein |
| CN111606978B (en) * | 2020-06-09 | 2023-03-17 | 河南省农业科学院 | Method for removing endotoxin in escherichia coli recombinant expression porcine parvovirus VP2 protein |
| CN113092767A (en) * | 2021-04-02 | 2021-07-09 | 丹娜(天津)生物科技股份有限公司 | Limulus reagent freeze-dried microsphere and preparation method and application thereof |
| CN113092767B (en) * | 2021-04-02 | 2024-03-12 | 丹娜(天津)生物科技股份有限公司 | Limulus reagent freeze-dried microsphere and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6674727B2 (en) | 2020-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5730433B2 (en) | Method for producing sheet cell culture | |
| JP5341059B2 (en) | Stem cell suspension | |
| JP6861627B2 (en) | Cryopreservation method of sheet-shaped cell culture | |
| CN103702674B (en) | Composition, purposes and the preparation of platelet cracking content | |
| JP7282232B2 (en) | Methods for modifying adherent cell cultures | |
| JP6674727B2 (en) | How to remove endotoxin from cells | |
| JP6412696B2 (en) | Serum preparation method and instrument | |
| JP5753874B2 (en) | Cell viability decline inhibitor | |
| WO2018168983A1 (en) | Method for producing sheet-shaped cell culture | |
| US10221389B2 (en) | Method of producing cell population with high target cell purity | |
| JP6756502B2 (en) | Cell culture and its production method | |
| JP6670040B2 (en) | Method for producing sheet-shaped cell culture | |
| JP7262443B2 (en) | Sheet-like cell culture with penetrating structures | |
| WO2017195179A1 (en) | Solution for the preservation, transport and application of stem cells | |
| JP2021052661A (en) | Buffer for diluting cryopreserved cell including pluripotent stem cell | |
| JP2017176004A (en) | Cell cultures and production methods thereof | |
| WO2020067442A1 (en) | Method for cryopreserving cells | |
| WO2020067434A1 (en) | Method for cryopreserving cells | |
| WO2021065971A1 (en) | Dilution buffer solution for cryopreserved cells | |
| JP2019154363A (en) | Medical cell culture | |
| WO2019177146A1 (en) | Method for producing sheet-shaped cell culture | |
| JP2022159210A (en) | Method for producing frozen adhesive stem cell |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160303 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170203 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20170316 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170404 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170913 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171113 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180705 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181005 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20181018 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20181221 |
|
| RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20191120 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20191121 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200309 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6674727 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |